Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Abstract

In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, NCT00239681.)